Envista Holdings Corp Stock: price and directors' dealings · United States · SEC (Form 4)

About Envista Holdings Corp

Envista Holdings Corp. (NYSE: NVST) is a US-listed company traded on the NYSE in the United States, focused on dental technologies and consumables. The company serves dentists, orthodontists, labs, and dental practices with a broad portfolio designed to diagnose, treat, and prevent oral diseases, while also improving the aesthetics of the smile. Its positioning is that of a global dental-care platform with a diversified brand portfolio and commercial reach in more than 130 countries. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1757073/000175707325000022/nvst_2024annualreportx42425.pdf?utm_source=openai)) Envista was formed in 2018 as a wholly owned subsidiary of Danaher and then separated through its IPO in 2019. That heritage matters because the company continues to use the Envista Business System (EBS) as a core operating framework, reflecting a disciplined continuous-improvement culture. Its headquarters are in Brea, California, United States. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1757073/000175707325000022/nvst_2024annualreportx42425.pdf?utm_source=openai)) The business is organized into two main segments. Specialty Products & Technologies includes dental implant systems, regenerative solutions, dental prosthetics, associated treatment software and technologies, as well as orthodontic bracket systems, aligners, and lab products. Equipment & Consumables covers diagnostic solutions, dental equipment, consumables, and related services. For investors, this mix is important because it combines recurring consumable revenue with more technology-led, differentiated offerings. In 2024, about 85% of sales came from consumables, services, and spare parts, which supports a relatively resilient revenue profile. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1757073/000175707325000022/nvst_2024annualreportx42425.pdf?utm_source=openai)) From a competitive standpoint, Envista is one of the largest global dental products companies. Its advantages include the breadth of its portfolio, strong international distribution, and its ability to serve multiple clinical use cases, from implant-based tooth replacement to orthodontics, imaging, and consumables. The company highlights brands such as Nobel Biocare, Ormco, DEXIS, and Kerr, which provide both market recognition and reach across professional dental channels. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1757073/000175707325000022/nvst_2024annualreportx42425.pdf?utm_source=openai)) Recent developments point to improving execution. In its 2025 results, Envista reported positive core revenue growth, margin improvement, higher R&D investment, and progress at Spark, its aligner business, which achieved positive operating margin in the second half of 2025. The company also noted lower G&A expense and continued share repurchases. For francophone investors, the key investment case is a specialized healthcare company with global exposure, a strong recurring-revenue base, and an operating turnaround that appears to be progressing. ([investors.envistaco.com](https://investors.envistaco.com/2026-02-05-Envista-Reports-Fourth-Quarter-2025-Results?utm_source=openai))